Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 5,390

Document Document Title
WO/2019/094732A1
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...  
WO/2019/090069A1
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2019/090076A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2019/083001A1
The present invention provides: a method for producing a benzoyl formic acid compound in an industrially advantageous manner; and a method for efficiently producing a pyridazine compound using the method for producing a benzoyl formic ac...  
WO/2019/076934A1
The present invention provides, inter alia, a process for producing a compound of Formula (I): wherein A1, R1, R2, R3, R4, R5 and R6 are as defined herein. The present invention further provides intermediate compounds utilised in said pr...  
WO/2019/076930A1
The present invention provides, inter alia, a process for producing a compound of Formula (I): wherein A1, R1, R2, R3, R4, R5 and R6 are as defined herein. The present invention further provides intermediate compounds utilised in said pr...  
WO/2019/074241A1
The present invention relates to a compound represented by Chemical Formula 1 in the description or a pharmaceutically acceptable salt thereof. A compound and a pharmaceutically acceptable salt thereof according to the present invention ...  
WO/2019/055966A3
Disclosed are compounds according to Formula (A), and related tautomers and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (A).  
WO/2019/051396A1
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...  
WO/2019/046848A1
Herein polymers and particles which comprise a plurality of dihydropyridazine or hydropyridazine functional groups are described. Methods for their formation and specific monomers which may be used in their formation are also described. ...  
WO/2019/045824A1
The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.  
WO/2019/034692A1
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of...  
WO/2019/034693A1
The present invention relates to sulfonylureas and sulfonylthioureas comprising a monocyclic imidazolyl group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions compri...  
WO/2019/025554A1
The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)- one derivatives of formula (I) : The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)- one derivatives of formula (I) :  
WO/2019/025467A1
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...  
WO/2019/023553A1
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...  
WO/2019/008029A1
The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 ...  
WO/2019/002173A1
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...  
WO/2019/005484A1
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, Formula (1) wherein W, R1, R2, R3, n, R4, R5, R6, L and G are as defined in the disclosure. Also disclosed are compositions containing the co...  
WO/2018/234346A1
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/214736A1
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...  
WO/2018/213150A1
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...  
WO/2018/210296A1
The present invention relates to a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor.  
WO/2018/201167A3
Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods ...  
WO/2018/195439A3
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.  
WO/2018/195439A2
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.  
WO/2018/183432A1
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as herbicides (Formula 1), wherein R1, R2, L, G and W are as defined in the disclusur...  
WO/2018/183587A1
The present invention generally relates to 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles as a ubiquitin specific protease 7 (USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer...  
WO/2018/177126A1
A phthalazone hydroxamic acid compound, a preparation method therefor and an application thereof. A structural formula of the compound is represented by formula I: (I), wherein R1 and R2 are hydrogen atoms or halogen, Y is an oxygen atom...  
WO/2018/167468A1
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...  
WO/2018/167800A1
The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. T...  
WO/2018/165615A1
The invention is directed to roles for PARP-1 in disease.  
WO/2018/157232A1
Compositions comprising modulators of N-terminus activation of the androgen receptor, such as EPI-002 and EPI-506, and a second therapeutic agent are provided. Use of such compositions for treatment of various indications, including pros...  
WO/2018/153279A1
The present invention provides novel dihydropyridophthalazinone compounds of Formula (I) as PARP inhibitors, and their pharmaceutically acceptable salts, solvates, hydrates, prodrugs and metabolites thereof, the preparation thereof, and ...  
WO/2018/149991A1
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...  
WO/2018/146010A1
The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds us...  
WO/2018/140512A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...  
WO/2018/133579A1
Provided in the present invention are a ruthenium metal complex of which the molecular formula is L3Ir, applications thereof, and an organic electroluminescent component, where Ir is the center metal atom, L is a ligand, and the structur...  
WO/2018/131690A1
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...  
WO/2018/128084A1
Provided is a polymerizable compound that has low-wavelength dispersion or reverse-wavelength dispersion, does not readily bubble when made into a coating material, has excellent substrate adhesion when made into a film-like polymer, and...  
WO/2018/115069A1
The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC),especially the α2δ-1 subunit of voltage-gated calcium channels or dua...  
WO/2018/116107A1
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...  
WO/2018/111787A1
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause...  
WO/2018/106284A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2018/093696A1
The present invention relates to a compound represented by formula I': and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ("DGAT2") and may be useful in the tre...  
WO/2018/085813A1
Disclosed herein are thieno[2,3-b:5,4-c']dipyridin-8-amine and pyrido[4',3':4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also ...  
WO/2018/082964A1
Process for the production of compounds (I). their salts, tautomers, or enantiomers; by reaction of compounds (II) their salts, tautomers, or enantiomers; with compounds (III) their salts, tautomers, or enantiomers. And compounds III in ...  
WO/2018/081377A1
The present disclosure is directed to compounds that modulate, e.g., address underlying defects in cellular processing of CFTR (cystic fibrosis transmembrane conductance regulator) activity.  
WO/2018/080216A1
The present invention relates to a compound represented by Chemical Formula 1, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of cardiov...  

Matches 1 - 50 out of 5,390